最新的临床证据和小规模肺癌的操作策略
Juntendo Iji zasshi = Juntendo medical journal
|June 24, 2024
概括
在非小细胞肺癌 (NSCLC) 中存在地面玻璃不透明性 (GGO),表明不论固体瘤大小,预后都有利. 没有GGO的纯固体瘤表现出更具攻击性的行为,这表明GGO的存在对分期至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
背景情况:
- 目前的非小细胞肺癌 (NSCLC) 阶段取决于瘤大小,第8个TNM分类强调CT扫描上的固体成分大小.
- 关于仅仅依靠放射性固体大小进行临床T分期存在争论,特别是关于地面玻璃不透明度 (GGO) 的预后意义.
研究的目的:
- 评估地面玻璃不透明度 (GGO) 在非小细胞肺癌 (NSCLC) 的预后影响.
- 调查与没有转基因组分的NSCLC之间的临床和病理差异.
- 倡导将GGO存在/缺席纳入未来的NSCLC分期系统.
主要方法:
- 审查有关NSCLC特征的机构报告和全国数据.
- 对放射性发现的分析,包括薄截面计算机断层扫描上的固体组件大小和GGO存在.
- 与GGO和无GGO瘤之间的临床和病理方面的比较,预后,复发模式和手术策略.
主要成果:
- 在NSCLC中存在GGO成分与有利的预后有关,独立于固体成分大小.
- 纯固体NSCLC (没有GGO) 与部分固体瘤相比,表现出更恶性的行为,更差的预后和多样化的组织学类型.
- 有关基线特征,预后,复发,行为和操作策略的显著差异存在于带有和没有GGO的NSCLC之间.
结论:
- 地面玻璃不透明度 (GGO) 是影响NSCLC预后和行为的关键因素.
- 在NSCLC中,GGO的存在或缺失应被认为是未来临床T分类的重要参数.
- 对GGO的放射性评估为NSCLC管理提供了超越实体瘤大小的宝贵见解.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
